Use of nebulized liposomal amphotericin B and posaconazole as antifungal prophylaxis in patients with severe SARS-CoV2 infection in intensive care unit.
Benedetta FumarolaLiana SignoriniSilvia LorenzottiPaola LanzaBarbara SaccaniEvelyn Van HauwermeirenAlice MulèSimone PivaMatteo RotaFrancesco ZuccalàFrancesco Antonio RasuloMatteo FilippiniAlberto BertazzoliGiovanni Del FabroAlberto MatteelliPublished in: Infection (2024)
AFP was associated with reduced incidence and mortality from CAPA and was well tolerated in patients with severe COVID-19. Posaconazole concentrations below the efficacy threshold in almost all patients may be attributable to drug interactions and prompt further studies to define its clinical significance.
Keyphrases
- intensive care unit
- end stage renal disease
- coronavirus disease
- chronic kidney disease
- ejection fraction
- risk factors
- sars cov
- newly diagnosed
- early onset
- prognostic factors
- type diabetes
- cardiovascular disease
- mechanical ventilation
- patient reported outcomes
- coronary artery disease
- acute respiratory distress syndrome
- patient reported